Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Patients
Investors + Media

>> Sub navigation

Careers
Contact

Investors + Media: Press Releases

Press Releases

Year

May 29, 2020

Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

May 20, 2020

Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders

May 13, 2020

Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

April 28, 2020

Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update

April 13, 2020

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

March 31, 2020

Arvinas to Present at the American Society of Clinical Oncology Annual Meeting

March 16, 2020

Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2020. All Rights Reserved.

Contact Privacy Policy Terms & Conditions